Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis

UnknownOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

April 30, 2019

Conditions
Progressive Multiple Sclerosis
Interventions
DRUG

biotin

This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.

OTHER

propensity score

This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.

Trial Locations (1)

63003

CHU Clermont-FERRAND, Clermont-Ferrand

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OFSEP (Observatoire Français de la Sclérose en Plaques)

UNKNOWN

collaborator

SFSEP (Société Francophone de la Sclérose en Plaques)

UNKNOWN

collaborator

MedDay Pharmaceuticals SA

INDUSTRY

lead

University Hospital, Clermont-Ferrand

OTHER

NCT03552211 - Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter